Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach

Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach

Richard F Pollock,1 Barrie Chubb,2 William J Valentine,1 Simon Heller3 1Health Economics and Outcomes Research, Ossian Health Economics and Communications GmbH, Basel, Switzerland; 2EU-HEOR, Novo Nordisk Limited, Gatwick, UK; 3Department of Oncology & Metabolism, The University of Sheffield,...

Full description

Bibliographic Details
Main Authors: Pollock RF, Chubb B, Valentine WJ, Heller S
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
Cost-Benefit Analysis
Insulin
Diabetes Mellitus
Type 1
Type 2
Hypoglycemia
Online Access:https://www.dovepress.com/evaluating-the-cost-effectiveness-of-insulin-detemir-versus-neutral-pr-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/evaluating-the-cost-effectiveness-of-insulin-detemir-versus-neutral-pr-peer-reviewed-article-DMSO

Similar Items